BIOTRONIK Blog

Explore our latest insightful interviews and articles

Patient reading on the iPad

Blog Stories

Filter and Search

46 blog articles
Blog

“I Now Know What Really Matters in Life”

Around 49 million people in the EU suffer from cardiovascular diseases. Here, Coronary Artery Disease (CAD) accounts for the major share of the diseases. In this context, narrowing of vessels by atherosclerotic processes is closely linked to an unhealthy lifestyle. This was also the case for the North Rhine-Westphalian deacon Rainer Beerhenke. After successful stent placement and a bypass surgery in 2021, the 58-year-old is again living life to the full and is one of the first patients to take part in the EU-funded TIMELY project, which aims to improve the range of therapies for CAD patients.

Subscribe for our News

I prefer to be contacted by
*Fields are mandatory.

Latest Press Releases

Show all press releases
BERLIN, Germany
Press Release

AI-Supported Telemedicine Platform Aims to Improve the Health of Patients After Myocardial Infarction and Prevent Reinfarctions

The TIMELY consortium announced today the enrollment of the first patient in the randomized controlled clinical TIMELY trial. The TIMELY study investigates to what extent the AI-supported TIMELY platform improves the health of myocardial infarction (MI) patients and other patients with coronary heart disease after cardiac rehabilitation. Around 1.8 million people in the European Union die each year from coronary heart disease. 1 To prevent reinfarctions, patients receive cardiac rehabilitation to support necessary changes in lifestyle habits, such as diet and increased physical activity
COPENHAGEN, Denmark
Press Release

BIOLUX P-III BENELUX All-Comers Registry Demonstrates Safety and Efficacy of BIOTRONIK’s Drug-Coated Balloon in Isolated Popliteal Lesions at 24 Months

BIOTRONIK announced the two-year-results from the BIOLUX P-III BENELUX all-comers registry, presented by Principal Investigator Prof. Frank Vermassen at CIRSE 2023 in Copenhagen, Denmark. 1 The prospective, international, multicenter post-market registry evaluated the safety and efficacy of the Passeo ®-18 Lux ® drug-coated balloon (DCB) catheter in isolated popliteal artery lesions. This indication is considered a difficult vessel bed to treat due to its biomechanical constraints that usually preclude the placement of stents. BIOLUX P-III BENELUX registry enrolled 99 patients in Belgium, the
BIOPACT Two-Year-Data Presentation at PVI
BÜLACH, Switzerland
Press Release

Two-Year BIOPACT Randomized Controlled Trial (RCT) Analysis Demonstrates “Persistent Excellence” for Low-Profile Passeo-18 Lux DCB

BIOTRONIK announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 24 months. 1 The prospective, multicenter, core-lab adjudicated non-inferiority trial enrolled 302 patients in Austria, Belgium, France and Switzerland with

Press Contact